Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis extends Galvus resubmission target to mid-‘09

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

An FDA-requested safety study of Novartis' antidiabetic Galvus (vildagliptin) will take at least six months, not "weeks" as the firm originally suggested, and will enroll "several hundred" patients with renal impairment, Head of Pharma Development James Shannon tells a July 17 earnings call. The study, requested in FDA's Feb. 23 "approvable" letter for the dipeptidyl peptidase-4 agent, responds to concerns about skin lesions seen in primates and healthy volunteers at four to six times the proposed therapeutic dose, Shannon said. FDA is concerned that susceptible populations may get to those levels, he explained. FDA has requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles (1Pharmaceutical Approvals Monthly March 2007, p. 20). Novartis submitted a study protocol in June and, if FDA agrees, anticipates starting the renal impairment study in the fourth quarter of 2007. "We would resubmit the dossier to the FDA sometime in mid-2009," Shannon predicted…

You may also be interested in...

Novartis Galvus "approvable"

Novartis will likely have to conduct another clinical trial of its dipeptidyl peptidase-4 inhibitor Galvus (vildagliptin) following a Feb. 23 "approvable" letter. FDA had earlier requested a three-month extension of the initial November 2006 user fee date due to concerns about necrotoxicity seen in preclinical studies. Novartis said FDA remains concerned about the skin toxicity and that some patients may be predisposed to achieving high plasma levels with standard doses. FDA requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles. Cleared in October, FDA did not see skin toxicity in Merck's Januvia (sitagliptin), which was the first DPP-4 inhibitor to be approved (1Pharmaceutical Approvals Monthly January 2007, p. 29)...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts